Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
M.D.Houslay,
and
D.R.Adams
(2010).
Putting the lid on phosphodiesterase 4.
|
| |
Nat Biotechnol, 28,
38-40.
|
|
|
|
|
|
|
B.Chang,
T.Grau,
S.Dangel,
R.Hurd,
B.Jurklies,
E.C.Sener,
S.Andreasson,
H.Dollfus,
B.Baumann,
S.Bolz,
N.Artemyev,
S.Kohl,
J.Heckenlively,
and
B.Wissinger
(2009).
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
|
| |
Proc Natl Acad Sci U S A, 106,
19581-19586.
|
|
|
|
|
|
|
J.Pandit,
M.D.Forman,
K.F.Fennell,
K.S.Dillman,
and
F.S.Menniti
(2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
|
| |
Proc Natl Acad Sci U S A, 106,
18225-18230.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
D.M.Halpin
(2008).
ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
|
| |
Int J Chron Obstruct Pulmon Dis, 3,
543-561.
|
|
|
|
|
|
|
D.Spina
(2008).
PDE4 inhibitors: current status.
|
| |
Br J Pharmacol, 155,
308-315.
|
|
|
|
|
|
|
R.Arya,
S.Aslam,
S.Gupta,
R.S.Bora,
L.Vijayakrishnan,
P.Gulati,
S.Naithani,
S.Mukherjee,
S.Dastidar,
A.Bhattacharya,
and
K.S.Saini
(2008).
Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum.
|
| |
Biotechnol J, 3,
938-947.
|
|
|
|
|
|
|
S.Liu,
M.N.Mansour,
K.S.Dillman,
J.R.Perez,
D.E.Danley,
P.A.Aeed,
S.P.Simons,
P.K.Lemotte,
and
F.S.Menniti
(2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
|
| |
Proc Natl Acad Sci U S A, 105,
13309-13314.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
H.Wang,
Y.Liu,
J.Hou,
M.Zheng,
H.Robinson,
and
H.Ke
(2007).
Structural insight into substrate specificity of phosphodiesterase 10.
|
| |
Proc Natl Acad Sci U S A, 104,
5782-5787.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
H.Wang,
Z.Yan,
J.Geng,
S.Kunz,
T.Seebeck,
and
H.Ke
(2007).
Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
|
| |
Mol Microbiol, 66,
1029-1038.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
J.D.Ye,
C.D.Barth,
P.S.Anjaneyulu,
T.Tuschl,
and
J.A.Piccirilli
(2007).
Reactions of phosphate and phosphorothiolate diesters with nucleophiles: comparison of transition state structures.
|
| |
Org Biomol Chem, 5,
2491-2497.
|
|
|
|
|
|
|
M.Conti,
and
J.Beavo
(2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
|
| |
Annu Rev Biochem, 76,
481-511.
|
|
|
|
|
|
|
G.Down,
S.Siederer,
S.Lim,
and
P.Daley-Yates
(2006).
Clinical pharmacology of Cilomilast.
|
| |
Clin Pharmacokinet, 45,
217-233.
|
|
|
|
|
|
|
P.M.Brown,
T.T.Caradoc-Davies,
J.M.Dickson,
G.J.Cooper,
K.M.Loomes,
and
E.N.Baker
(2006).
Crystal structure of a substrate complex of myo-inositol oxygenase, a di-iron oxygenase with a key role in inositol metabolism.
|
| |
Proc Natl Acad Sci U S A, 103,
15032-15037.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
Q.Xu,
R.Schwarzenbacher,
D.McMullan,
P.Abdubek,
S.Agarwalla,
E.Ambing,
H.Axelrod,
T.Biorac,
J.M.Canaves,
H.J.Chiu,
A.M.Deacon,
M.DiDonato,
M.A.Elsliger,
A.Godzik,
C.Grittini,
S.K.Grzechnik,
J.Hale,
E.Hampton,
G.W.Han,
J.Haugen,
M.Hornsby,
L.Jaroszewski,
H.E.Klock,
E.Koesema,
A.Kreusch,
P.Kuhn,
S.A.Lesley,
M.D.Miller,
K.Moy,
E.Nigoghossian,
J.Paulsen,
K.Quijano,
R.Reyes,
C.Rife,
G.Spraggon,
R.C.Stevens,
H.van den Bedem,
J.Velasquez,
A.White,
G.Wolf,
K.O.Hodgson,
J.Wooley,
and
I.A.Wilson
(2006).
Crystal structure of virulence factor CJ0248 from Campylobacter jejuni at 2.25 A resolution reveals a new fold.
|
| |
Proteins, 62,
292-296.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
V.Vasta,
M.Shimizu-Albergine,
and
J.A.Beavo
(2006).
Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A.
|
| |
Proc Natl Acad Sci U S A, 103,
19925-19930.
|
|
|
|
|
|
|
Y.Xiong,
H.T.Lu,
Y.Li,
G.F.Yang,
and
C.G.Zhan
(2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
Biophys J, 91,
1858-1867.
|
|
|
|
|
|
|
A.Castro,
M.J.Jerez,
C.Gil,
and
A.Martinez
(2005).
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
|
| |
Med Res Rev, 25,
229-244.
|
|
|
|
|
|
|
A.Trifilieff,
T.H.Keller,
N.J.Press,
T.Howe,
P.Gedeck,
D.Beer,
and
C.Walker
(2005).
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
|
| |
Br J Pharmacol, 144,
1002-1010.
|
|
|
|
|
|
|
G.L.Card,
L.Blasdel,
B.P.England,
C.Zhang,
Y.Suzuki,
S.Gillette,
D.Fong,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2005).
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
|
| |
Nat Biotechnol, 23,
201-207.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
J.A.Doudna,
and
J.R.Lorsch
(2005).
Ribozyme catalysis: not different, just worse.
|
| |
Nat Struct Mol Biol, 12,
395-402.
|
|
|
|
|
|
|
K.Y.Zhang,
P.N.Ibrahim,
S.Gillette,
and
G.Bollag
(2005).
Phosphodiesterase-4 as a potential drug target.
|
| |
Expert Opin Ther Targets, 9,
1283-1305.
|
|
|
|
|
|
|
L.I.Castro,
C.Hermsen,
J.E.Schultz,
and
J.U.Linder
(2005).
Adenylyl cyclase Rv0386 from Mycobacterium tuberculosis H37Rv uses a novel mode for substrate selection.
|
| |
FEBS J, 272,
3085-3092.
|
|
|
|
|
|
|
V.Vasta,
W.K.Sonnenburg,
C.Yan,
S.H.Soderling,
M.Shimizu-Albergine,
and
J.A.Beavo
(2005).
Identification of a new variant of PDE1A calmodulin-stimulated cyclic nucleotide phosphodiesterase expressed in mouse sperm.
|
| |
Biol Reprod, 73,
598-609.
|
|
|
|
|
|
|
M.Conti
(2004).
A view into the catalytic pocket of cyclic nucleotide phosphodiesterases.
|
| |
Nat Struct Mol Biol, 11,
809-810.
|
|
|
|
|
|
|
Q.Huai,
H.Wang,
W.Zhang,
R.W.Colman,
H.Robinson,
and
H.Ke
(2004).
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
|
| |
Proc Natl Acad Sci U S A, 101,
9624-9629.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
S.Kunz,
T.Kloeckner,
L.O.Essen,
T.Seebeck,
and
M.Boshart
(2004).
TbPDE1, a novel class I phosphodiesterase of Trypanosoma brucei.
|
| |
Eur J Biochem, 271,
637-647.
|
|
|
|
|
|
|
Y.Adachi,
J.Yoshida,
Y.Kodera,
A.Kato,
Y.Yoshikawa,
Y.Kojima,
and
H.Sakurai
(2004).
A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes.
|
| |
J Biol Inorg Chem, 9,
885-893.
|
|
|
|
|
|
|
B.J.Sung,
K.Y.Hwang,
Y.H.Jeon,
J.I.Lee,
Y.S.Heo,
J.H.Kim,
J.Moon,
J.M.Yoon,
Y.L.Hyun,
E.Kim,
S.J.Eum,
S.Y.Park,
J.O.Lee,
T.G.Lee,
S.Ro,
and
J.M.Cho
(2003).
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
|
| |
Nature, 425,
98.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
G.S.Baillie,
A.Sood,
I.McPhee,
I.Gall,
S.J.Perry,
R.J.Lefkowitz,
and
M.D.Houslay
(2003).
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
|
| |
Proc Natl Acad Sci U S A, 100,
940-945.
|
|
|
|
|
|
|
J.Arp,
M.G.Kirchhof,
M.L.Baroja,
S.H.Nazarian,
T.A.Chau,
C.A.Strathdee,
E.H.Ball,
and
J.Madrenas
(2003).
Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.
|
| |
Mol Cell Biol, 23,
8042-8057.
|
|
|
|
|
|
|
M.J.Frame,
R.Tate,
D.R.Adams,
K.M.Morgan,
M.D.Houslay,
P.Vandenabeele,
and
N.J.Pyne
(2003).
Interaction of caspase-3 with the cyclic GMP binding cyclic GMP specific phosphodiesterase (PDE5a1).
|
| |
Eur J Biochem, 270,
962-970.
|
|
|
|
|
|
|
A.Rascón,
S.H.Soderling,
J.B.Schaefer,
and
J.A.Beavo
(2002).
Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei.
|
| |
Proc Natl Acad Sci U S A, 99,
4714-4719.
|
|
|
|
|
|
|
A.Robichaud,
P.B.Stamatiou,
S.L.Jin,
N.Lachance,
D.MacDonald,
F.Laliberté,
S.Liu,
Z.Huang,
M.Conti,
and
C.C.Chan
(2002).
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
|
| |
J Clin Invest, 110,
1045-1052.
|
|
|
|
|
|
|
M.E.Meima,
R.M.Biondi,
and
P.Schaap
(2002).
Identification of a novel type of cGMP phosphodiesterase that is defective in the chemotactic stmF mutants.
|
| |
Mol Biol Cell, 13,
3870-3877.
|
|
|
|
|
|
|
S.H.Hung,
K.S.Madhusoodanan,
R.L.Boyd,
J.L.Baldwin,
R.F.Colman,
and
R.W.Colman
(2002).
A nonhydrolyzable reactive cAMP analogue, (S(p))-8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic S-(methyl)monophosphorothioate, irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase at micromolar concentrations.
|
| |
Biochemistry, 41,
2962-2969.
|
|
|
|
|
|
|
S.J.MacKenzie,
G.S.Baillie,
I.McPhee,
C.MacKenzie,
R.Seamons,
T.McSorley,
J.Millen,
M.B.Beard,
G.van Heeke,
and
M.D.Houslay
(2002).
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).
|
| |
Br J Pharmacol, 136,
421-433.
|
|
|
|
|
|
|
W.Richter
(2002).
3',5' Cyclic nucleotide phosphodiesterases class III: members, structure, and catalytic mechanism.
|
| |
Proteins, 46,
278-286.
|
|
|
|
|
|
|
K.L.Dodge,
S.Khouangsathiene,
M.S.Kapiloff,
R.Mouton,
E.V.Hill,
M.D.Houslay,
L.K.Langeberg,
and
J.D.Scott
(2001).
mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module.
|
| |
EMBO J, 20,
1921-1930.
|
|
|
|
|
|
|
N.A.Glavas,
C.Ostenson,
J.B.Schaefer,
V.Vasta,
and
J.A.Beavo
(2001).
T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3.
|
| |
Proc Natl Acad Sci U S A, 98,
6319-6324.
|
|
|
|
|
|
|
W.Zhang,
H.Ke,
A.P.Tretiakova,
B.Jameson,
and
R.W.Colman
(2001).
Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
|
| |
Protein Sci, 10,
1481-1489.
|
|
|
|
|
|
|
S.H.Francis,
I.V.Turko,
K.A.Grimes,
and
J.D.Corbin
(2000).
Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5.
|
| |
Biochemistry, 39,
9591-9596.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
351 a.a.
_ZN
_MG
